BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 21505062)

  • 1. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
    Kanai R; Wakimoto H; Martuza RL; Rabkin SD
    Clin Cancer Res; 2011 Jun; 17(11):3686-96. PubMed ID: 21505062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
    Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
    Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
    Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
    Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
    Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
    J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
    Jahan N; Lee JM; Shah K; Wakimoto H
    Int J Cancer; 2017 Oct; 141(8):1671-1681. PubMed ID: 28567859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
    Sgubin D; Wakimoto H; Kanai R; Rabkin SD; Martuza RL
    Stem Cells Transl Med; 2012 Apr; 1(4):322-32. PubMed ID: 23197811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
    Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
    Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

  • 11. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
    Kardani K; Sanchez Gil J; Rabkin SD
    Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
    Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF
    mBio; 2018 Sep; 9(5):. PubMed ID: 30228241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
    Zhang W; Fulci G; Wakimoto H; Cheema TA; Buhrman JS; Jeyaretna DS; Stemmer Rachamimov AO; Rabkin SD; Martuza RL
    Neoplasia; 2013 Jun; 15(6):591-9. PubMed ID: 23730207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling.
    Hou Y; Sun B; Liu W; Yu B; Shi Q; Luo F; Bai Y; Feng H
    Theranostics; 2021; 11(2):555-566. PubMed ID: 33391492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.
    Kanai R; Zaupa C; Sgubin D; Antoszczyk SJ; Martuza RL; Wakimoto H; Rabkin SD
    J Virol; 2012 Apr; 86(8):4420-31. PubMed ID: 22345479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
    Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
    J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
    Saha D; Martuza RL; Rabkin SD
    Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
    Passaro C; Alayo Q; De Laura I; McNulty J; Grauwet K; Ito H; Bhaskaran V; Mineo M; Lawler SE; Shah K; Speranza MC; Goins W; McLaughlin E; Fernandez S; Reardon DA; Freeman GJ; Chiocca EA; Nakashima H
    Clin Cancer Res; 2019 Jan; 25(1):290-299. PubMed ID: 30279232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
    Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
    Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
    McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
    Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.